| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| NeoGenesis Pharmaceuticals, Inc. |
| 840 Memorial Drive, Cambridge, MA 02139 * (617) 868-1500 |
| Business Description | The company is focused on the discovery of small molecule drugs on a proteome and genome-wide scale. They believe that they are the only company currently capable of delivering small molecule drug candidates for virtually every medically important protein encoded by the human genome. |
|
Filing Information IPO has been | |||
| To Trade As | NGPI (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 11/16/2001 |
| Domestic Shares Filed | 6,200,000 | Filing Range | $9.00 - $10.00 |
| Foreign Shares Filed | 0 | Offering Amount | $58,900,000 |
| Company Shares | 6,200,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| J.P. Morgan & Co. | Lead Manager | (212) 648-0517 |
| Bear, Stearns & Co. Inc. | Co-manager | (212) 272-4850 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1997 | 12/31/1998 | 12/31/1999 | 12/31/2000 | 9/30/2000 | 9/30/2001 | |
| Revenues | - | 0.000 | 0.568 | 1.867 | 0.759 | 0.759 | 2.647 |
| Income from Oper. | - | -1.169 | 3.817 | 4.848 | 6.899 | -3.981 | -8.396 |
| Net Income | - | -1.169 | -3.276 | 3.139 | -5.390 | -4.046 | -7.661 |
| E.P.S | - | -0.590 | -1.130 | -0.860 | -1.140 | -0.910 | -1.400 |
| Revenue Growth (%) | - | - | 228.70 | -59.347 | 248.75 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | 672.01 | 259.67 | 908.96 | - | - |
| Net Profit Margin (%) | - | - | - | 168.13 | - | - | - |
| Cash Flow - Oper. | -3.62 | -2.50 | -3.08 | ||||
| Cash Flow - Inv. | -0.26 | -0.23 | -2.97 | ||||
| Cash Flow - Fin. | 22.37 | 3.54 | 25.37 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2001 | Financial Ratios | ||||
| Total Assets | 44.08 | Current Assets | 39.74 | Current Ratio | 6.29 |
| Total Liab. | 6.85 | Current Liab. | 6.32 | Debt Ratio | 15.53% |
| Total Equity | 37.24 | Working Cap. | 33.42 | Debt to Equity Ratio | 0.18 |
| Cash | 37.90 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for for research and development activities relating to our collaborations and internal drug development programs, the scaling and further development of our drug discovery technologies and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Bingham, Dana & Gould |
| Bank's Law Firm | Cahill Gordon & Reindel |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Celltech R&D; Limited | ||
| Caduceus Private Investments LP | ||
| Note: represents ownership of 5% or more prior to the offering. | ||